Values and trade-offs in responsible antibiotic behaviour and sustainable access: protocol for a comparative mixed-methods empirical ethics study in Sweden, Italy, and Bulgaria
4 affiliations
- 1Centre for Research Ethics & Bioethics (CRB), Department of Public Health and Caring Sciences, Uppsala University, Box 564, Uppsala, Sweden
- 2Bulgarian Association for Personalized Medicine (BAPEMED), Sofia, Bulgaria
- 3Institute for Biomedicine, Eurac Research, Bolzano, Italy
- 4Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
Abstract
Background: Antibiotic resistance arises through biological evolution but is also shaped by behavioural, sociocultural, and institutional factors. Promoting responsible antibiotic behaviour requires understanding how members of the public and relevant stakeholders perceive antibiotic use, stewardship, access, and responsibility, and the values and trade-offs that shape their decisions. This study aims to investigate these factors across three national contexts and to develop context-sensitive recommendations and a methodological framework for future research.
Methods: This protocol describes an ongoing comparative mixed-methods empirical ethics study conducted in Sweden, Italy, and Bulgaria from May 2025 to April 2028. The study comprises three connected components: semi-structured online interviews with 16–20 participants from four stakeholder groups in each country; a general-population survey incorporating a discrete choice experiment, with a minimum of 350 respondents per country; and iterative normative analysis using reflective equilibrium. The 3D Value Framework informs the interviews, which examine stakeholders’ reasoning about sustainable antibiotic access, stewardship, responsibility, and preparedness. Interview findings, relevant literature, and previous research will inform the survey attributes and scenarios. The survey will examine public preferences and trade-offs concerning antibiotic treatment, responsible behaviour, and sustainable access, alongside antibiotic knowledge, trust, prosociality, biospherism, gender-related perspectives, social norms, and values. The empirical findings will be interpreted in relation to ethical theories of justice and personal and collective responsibility. A One Health perspective informs the overall study.
Discussion: By bringing stakeholder reasoning and public preferences into dialogue with normative analysis, the study will examine how responsibility for preserving antibiotic effectiveness and sustainable access should be understood and distributed between individuals and institutional actors. It will also address the ethical implications of trade-offs between present and future access and the distribution of associated benefits and burdens. This empirical ethics approach is expected to support a context-sensitive account of justice and responsibility and to inform ethically justified antibiotic stewardship, policy, and communication.
Clinical trial number: Not applicable.
Related
- Empirical Antibiotic Initiation for Suspected Early-Onset Neonatal Infection in the Setting of Maternal GBS Screening and Intrapartum Antibiotic Prophylaxis: A Single-Center Retrospective Cohort Study
- Clinical outcomes of empirical antibiotic strategies in community-acquired pneumonia-associated sepsis: a propensity score-matched cohort study
- Effect of Antibiotic Incorporation on the Porosity of Polymethylmethacrylate (PMMA) Bone Cement: A Comparative Analysis
- Responsible use of large language models in digital health: an equity-first governance framework
- Deep leverage points for ethical and responsible AI in long-term care
BibTeX
@article{fernow2026values,
title = {{Values and trade-offs in responsible antibiotic behaviour and sustainable access: protocol for a comparative mixed-methods empirical ethics study in Sweden, Italy, and Bulgaria}},
author = {Josepine Fernow and Niklas Juth and Antonia Diukendjieva and Gergana Kyosovska and Deborah Mascalzoni and Roberta Biasiotto and Jorien Veldwijk and Mirko Ancillotti},
journal = {BMC Medical Ethics},
year = {2026},
month = nov,
doi = {10.1186/s12910-026-01651-9},
url = {https://doi.org/10.1186/s12910-026-01651-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Values and trade-offs in responsible antibiotic behaviour and sustainable access: protocol for a comparative mixed-methods empirical ethics study in Sweden, Italy, and Bulgaria
AU - Josepine Fernow
AU - Niklas Juth
AU - Antonia Diukendjieva
AU - Gergana Kyosovska
AU - Deborah Mascalzoni
AU - Roberta Biasiotto
AU - Jorien Veldwijk
AU - Mirko Ancillotti
PY - 2026
DA - 2026/11/03
JO - BMC Medical Ethics
DO - 10.1186/s12910-026-01651-9
UR - https://doi.org/10.1186/s12910-026-01651-9
AB - Background: Antibiotic resistance arises through biological evolution but is also shaped by behavioural, sociocultural, and institutional factors. Promoting responsible antibiotic behaviour requires understanding how members of the public and relevant stakeholders perceive antibiotic use, stewardship, access, and responsibility, and the values and trade-offs that shape their decisions. This study aims to investigate these factors across three national contexts and to develop context-sensitive recommendations and a methodological framework for future research. Methods: This protocol describes an ongoing comparative mixed-methods empirical ethics study conducted in Sweden, Italy, and Bulgaria from May 2025 to April 2028. The study comprises three connected components: semi-structured online interviews with 16–20 participants from four stakeholder groups in each country; a general-population survey incorporating a discrete choice experiment, with a minimum of 350 respondents per country; and iterative normative analysis using reflective equilibrium. The 3D Value Framework informs the interviews, which examine stakeholders’ reasoning about sustainable antibiotic access, stewardship, responsibility, and preparedness. Interview findings, relevant literature, and previous research will inform the survey attributes and scenarios. The survey will examine public preferences and trade-offs concerning antibiotic treatment, responsible behaviour, and sustainable access, alongside antibiotic knowledge, trust, prosociality, biospherism, gender-related perspectives, social norms, and values. The empirical findings will be interpreted in relation to ethical theories of justice and personal and collective responsibility. A One Health perspective informs the overall study. Discussion: By bringing stakeholder reasoning and public preferences into dialogue with normative analysis, the study will examine how responsibility for preserving antibiotic effectiveness and sustainable access should be understood and distributed between individuals and institutional actors. It will also address the ethical implications of trade-offs between present and future access and the distribution of associated benefits and burdens. This empirical ethics approach is expected to support a context-sensitive account of justice and responsibility and to inform ethically justified antibiotic stewardship, policy, and communication. Clinical trial number: Not applicable.
SN - 1472-6939
ER -